

Barber v L'Oreal USA, Inc.

2025 NY Slip Op 33487(U)

September 15, 2025

Supreme Court, New York County

Docket Number: Index No. 159701/2024

Judge: Mary V. Rosado

Cases posted with a "30000" identifier, i.e., 2013 NY Slip Op 30001(U), are republished from various New York State and local government sources, including the New York State Unified Court System's eCourts Service.

This opinion is uncorrected and not selected for official publication.

SUPREME COURT OF THE STATE OF NEW YORK
NEW YORK COUNTY

PRESENT: HON. MARY V. ROSADO PART 33M

Justice

-----X

JANICE BARBER,

Plaintiff,

- v -

LOREAL USA, INC., LOREAL USA PRODUCTS, INC., SOFT SHEEN-CARSON, LLC, STRENGTH OF NATURE, LLC, GODREJ SON HOLDINGS, INC., NAMASTE LABORATORIES, LLC D/B/A ORGANIC ROOT STIMULATOR, BEAUTY BELL ENTERPRISE D/B/A HOUSE OF CHEATHAM, INC. AND HOUSE OF CHEATHAM LLC, HOUSE OF CHEATHAM, LLC, LUSTER PRODUCTS, INC., AFAM CONCEPT, INC. D/B/A JF LABS, INC.

Defendant.

-----X

INDEX NO. 159701/2024
MOTION DATE 02/13/2025
MOTION SEQ. NO. 005

DECISION + ORDER ON MOTION

The following e-filed documents, listed by NYSCEF document number (Motion 005) 24, 25, 26, 27, 28, 72, 73, 74, 88, 89, 90

were read on this motion to/for DISMISS

Upon the foregoing documents, and after a final submission date of June 25, 2025, Defendants L'Oréal USA, Inc., L'Oréal USA Products, Inc., and SoftSheen-Carson LLC's (collectively, "L'Oréal USA") motion to dismiss Plaintiff Janice Barber's ("Plaintiff") Complaint pursuant to CPLR 3211(a)(1), (a)(5), and (a)(7) is granted in part and denied in part.

I. Background

This action arises out of Plaintiff's alleged exposure to hair straightening products which allegedly caused endometrial cancer. From 1982 to 2019, Plaintiff alleges she used numerous hair relaxer products manufactured and sold by Defendants. In October of 2018, Plaintiff was diagnosed with Stage II, grade 1 endometroid endometrial adenocarcinoma. Plaintiff now sues Defendants under numerous theories of liability seeking to recover damages related to her uterine

cancer diagnosis. L'Oréal USA responds with the instant pre-answer motion to dismiss. Plaintiff opposes and requests leave to amend or supplement her Complaint should the Court find her Complaint deficient in any regard.¹

II. Discussion

A. Preemption

L'Oréal USA's motion to dismiss Plaintiff's fifth through fifteenth causes of action based on express preemption is denied. Defendants argue Plaintiff's claims are expressly preempted by the Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. §301. Express preemption applies only where the plain language of a statute supersedes state law (*Doomes v Best Transit Corp.*, 17 NY3d 594, 601 [2011]). As held by the United States Supreme Court, there is a presumption against pre-emption, and pre-emption clauses are to be narrowly construed (*Cipollone v Liggett Group, Inc.* 505 U.S. 504, 505 [1992]; *see also Galper v JP Morgan Chase Bank, N.A.*, 802 F3d 437, 448 [2d Cir 2015]). The specific language which L'Oréal USA argues preempts many of Plaintiff's causes of action is found in 21 U.S.C. § 379s(a).

That provision provides:

"Except as provided in subsection (b), (d), or (e), no State or political subdivision of a State may establish or continue in effect any requirement for labeling or packaging of a cosmetic that is different from or in addition to, or that is otherwise not identical with, a requirement specifically applicable to a particular cosmetic or class of cosmetics under this chapter, the Poison Prevention Packaging Act of 1970 (15 U.S.C. 1471 et seq.), or the Fair Packaging and Labeling Act (15 U.S.C. 1451 et seq.)."

The exception to the preemption clause found at 21 U.S.C. § 379s(d) provides:

"Nothing in this section shall be construed to modify or otherwise affect any action or the liability of any person under the product liability law of any State."

¹ Plaintiff did not formally cross-move for a motion to amend, therefore the Court need not entertain this relief (*see Fifth Partners LLC v Foley*, 227 AD3d 543 [1st Dept 2024]; *Onofre v 243 Riverside Drive Corp.*, 232 AD3d 443, 443-444 [1st Dept 2024]).

A holistic review of Plaintiff's Complaint yields allegations that Defendants were negligent for failure to comply with the labelling requirements of 21 U.S.C. §§ 361, 362, and 21 C.F.R. § 740.1(a). Accepting Plaintiff's allegations as true, pursuant to § 361, titled "Adulterated cosmetics," Defendants' products should have been labelled and/or recalled as adulterated. That section specifically states a cosmetic is adulterated "[i]f it bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labelling thereof, or under such conditions of use as are customary or usual...." (*see* 21 U.S.C. § 361[a]). Moreover, pursuant to 21 U.S.C. 362(a), a cosmetic is misbranded "[i]f its labelling is false or misleading in any particular (*sic*)." Pursuant to 21 C.F.R. § 740.1(a), "[t]he label of a cosmetic product shall bear a warning statement whenever necessary or appropriate to prevent a health hazard that may be associated with the product."

L'Oréal USA's preemption argument is misguided in two respects. First, Plaintiff does not seek relief under state law causes of action that would impose a different or additional labeling requirement pursuant to the FDCA. Rather, Plaintiff is alleging state law causes of action based on purported violations of the FDCA's labeling requirement. Specifically, it is alleged that Defendants' products were marketed as "organic," "natural," "nourishing," and "healthy" even though there was scientific data showing certain ingredients in Defendants' products disrupt women's endocrine systems (NYSCEF Doc. 1 at ¶ 48). These ingredients are alleged to include, but are not limited to, phthalates, parabens, cyclosiloxanes, di-(2-ethylhexyl), octamethylcyclotetrasiloxane, lye, and formaldehyde (*Id.*). Given the presumption against preemption and construing 21 U.S.C. § 379s(a) narrowly and in conjunction with other sections of the FDCA, the Court finds Plaintiff's fifth through fifteenth causes of action are not expressly preempted. Indeed, § 379s(a) does not expressly bar plaintiffs from using common law causes of

action to seek damages based on a defendant's alleged failure to comply with the labeling requirements set forth in the FDCA.

Although L'Oréal USA relies on the Second Circuit's decision in *Critcher v. L'Oreal USA, Inc.*, 959 F.3d 31 (2d. Cir. 2020), the facts of that case are wholly distinguishable from the case at bar. Specifically, the putative class in *Critcher* sued because some purchased cosmetics could not be fully dispensed from cosmetics containers – causing purchased product to go to waste. The plaintiffs alleged they were “cheated” of the product they bought. They alleged there should have been a disclaimer that not all the cream bought was accessible to the consumer. *Critcher* was not a case involving alleged mislabeling based on the failure to warn about potentially cancer-causing ingredients. The Second Circuit specifically noted that the *Critcher* plaintiffs were not suing based on the effectiveness of the products, as Plaintiff does here. Moreover, the *Critcher* plaintiffs conceded that L'Oréal complied with the FDCA's federal labeling requirements, while here Plaintiff alleges those requirements have been violated. Thus, the Second Circuit's decision in *Critcher* is neither persuasive nor controlling.

The second reason that L'Oréal USA's preemption argument is misplaced is because it fails to consider that Plaintiff's causes of action five through fifteen may be categorized as product liability claims, or at the very least, are product liability adjacent, bringing them within the product liability exception contained in 21 U.S.C. § 379s(d). Indeed, it was for this reason that United States District Judge Mary M. Rowland, in ruling on defendants' joint motion to dismiss the plaintiffs' master complaint, found the numerous state law claims were not preempted (*see In re Hair Relaxer Marketing Sales Practices and Prods. Liab. Litig.*, 702 F.Supp.3d 692, 699-700 [ND Ill 2023]). Given the presumption against preemption, construing 21 U.S.C. § 379s(a) narrowly, and to ensure consistency in rulings, this Court adopts Judge Rowland's ruling in the ongoing

multidistrict litigation. Therefore, the motion to dismiss based on an express preemption defense is denied.

B. Statute of Limitations

L'Oréal USA's motion to dismiss Plaintiff's Complaint based on the statute of limitations is denied. The party seeking the benefit of the statute of limitations "must establish, prima facie, that the time within which to sue has expired" (*Mandour v Rafalsky*, 238 AD3d 637, 637 [1st Dept 2025] citing *Flintlock Constr. Servs., LLC v Rubin Fiorella & Friedman, LLP*, 188 AD3d 530, 531 [1st Dept 2020]). Where an issue of fact exists as to whether the statute of limitations has expired, the Court cannot deem the cause of action untimely (*Stringer v Kim*, 226 AD3d 607 [1st Dept 2024]). CPLR 214-c, which provides an exception to the generally applicable statute of limitations for claims asserted by toxic tort plaintiffs alleged to suffer injuries from latent conditions, is a remedial statute that is to be liberally construed (*Rothstein v Tennessee Gas Pipeline Co.*, 87 NY2d 90, 96 [1995]).

L'Oréal USA argues that because Plaintiff was diagnosed with cancer in 2018, but did not file her Complaint until October 17, 2024, her causes of action are barred by the three-year statute of limitations. However, CPLR 214-c(4) provides an exception to the statute of limitations in a toxic tort case such as this one. That provision provides:

"where the discovery of the cause of the injury is alleged to have occurred less than five years after discovery of the injury or when with reasonable diligence such injury should have been discovered, whichever is earlier, an action may be commenced or a claim filed within one year of such discovery of the cause of the injury; provided, however, if any such action is commenced or claim filed after the period in which it would otherwise have been authorized... the plaintiff or claimant shall be required to allege and prove that technical, scientific or medical knowledge and information sufficient to ascertain the cause of [her] injury had not been discovered, identified or prior to the expiration of the period within which the action or claim would have been authorized and that [she has otherwise satisfied the requirements of subdivisions two and three of [CPLR 214-c]).

The Court of Appeals has construed “discovery of the cause of the injury” to mean when the Plaintiff discovered that her symptoms were attributable to an “outside force” as opposed to an organic biological cause (*Matter of New York County DES Litig.*, 89 NY2d 506, 513 [1997]). Here, L’Oréal USA’s own motion papers, which adopt inconsistent positions, raise an issue of fact as to when there was sufficient scientific and medical consensus as to the link between Plaintiff’s cancer and L’Oréal USA’s hair relaxer products. On the one hand, L’Oréal USA argues that there is insufficient scientific literature for Plaintiff to sufficiently allege causation against L’Oréal USA. On the other hand, L’Oréal USA argues that there is sufficient scientific literature for Plaintiff’s claims to be barred by the statute of limitations. It is conceptually impossible for L’Oréal USA to meet its burden on a motion to dismiss pursuant to the statute of limitations while maintaining categorically inapposite positions as to the availability of scientific evidence regarding L’Oréal USA’s role in causing Plaintiff’s cancer. After further discovery, if it is ultimately established that there was sufficient reliable scientific evidence to link Plaintiff’s cancer to L’Oréal USA’s products prior to the deadlines set forth in CPLR 214(c), then L’Oréal USA may renew its statute of limitations argument on a motion for summary judgment (*see also Pompa v Burroughs Wellcome Co.*, 259 AD2d 18, 21-22 [3d Dept 1999]).

C. Failure to State a Claim

i. Failure to Warn (Second and Third Causes of Action)

L’Oréal USA’s motion to dismiss Plaintiff’s failure to warn causes of action is denied. L’Oréal USA argues the failure to warn claims fail because the Complaint does not allege L’Oréal USA’s knowledge of the defect. However, L’Oréal USA’s arguments are inappropriate on a pre-answer motion to dismiss, where this Court is required to accept the allegations as true. Although L’Oréal USA argues that there is insufficient scientific evidence to allege that it knew or should

have known about the dangers of certain ingredients, that is an argument appropriate for a motion for summary judgment, after further discovery has taken place and with competing expert affidavits, as opposed to a pre-answer motion to dismiss. For purposes of a pre-answer motion to dismiss, Plaintiff alleges sufficiently a failure to warn claim (*see, e.g. Liriano v Hobart Corp.*, 92 NY2d 232, 237 [1998] [manufacturers have “a duty to warn against latent dangers resulting from foreseeable uses of its product of which it knew or should have known.”])).

ii. Design and Manufacturing Defect (First and Fourth Causes of Action)

L’Oréal USA’s motion to dismiss Plaintiff’s design defect claim is denied. As long held by the Court of Appeals, a design defect claim arises when a product is “unreasonably dangerous for its intended use” or “whose utility does not outweigh the danger inherent in its introduction into the stream of commerce.” (*Voss v. Black & Decker Mfg. Co.*, 59 NY2d 102, 107 [1983]). Plaintiff explicitly alleges that L’Oréal USA’s hair relaxer products were unreasonably dangerous because they contained toxic ingredients which increased the risk of uterine cancer. Accepting the allegations as true, on a pre-answer motion to dismiss this is sufficient to state a design defect claim.

L’Oréal USA’s motion to dismiss Plaintiff’s manufacturing defect claim is granted. As a preliminary matter, Plaintiff failed to proffer arguments in opposition to the motion to dismiss her manufacturing defect claim and therefore it can be dismissed as abandoned (*Saidin v Negron*, 136 AD3d 458, 459 [1st Dept 2016]). Indeed, the heading of both the first and fourth causes of action purport to be for “Design and/or Manufacturing Defect.” However, a cause of action alleging design defect is distinct from a manufacturing defect claim, and a review of the allegations in the second and fourth causes of action clarify that Plaintiff is only alleging causes of action based on design defect. Indeed, to allege a manufacturing defect claim, there must be allegations that there

was a mistake or error during the manufacturing process which made a product defective (*Narvaez v Wadsworth*, 58 Misc.3d 12229[A] at 7 [Sup. Ct., Bx County, 2018] citing *Fitzpatrick v Currie*, 52 AD3d 1089, 1090 [3d Dept 2008]). Here, there are no allegations that products Plaintiff used were defectively manufactured and caused her injury – rather she alleges that the products were designed defectively by utilizing dangerous ingredients and failing to warn consumers about the dangers of those ingredients. Based on the lack of any particularized opposition and Plaintiff’s failure to distinguish her design defect allegations from her manufacturing defect allegations, Plaintiff’s manufacturing defect claims are dismissed.

iii. Negligence and Gross Negligence (Fifth Cause of Action)

L’Oréal USA’s motion to dismiss Plaintiff’s negligence and gross negligence claims is denied. Given the CPLR’s lenient pleading standard, coupled with Plaintiff’s detailed allegations in her Complaint, she has sufficiently alleged a negligence claim. Plaintiff has also alleged adequately a gross negligence claim, which requires allegations that a defendant’s conduct “evinces a reckless disregard for the rights of others or ‘smacks’ of intentional wrongdoing.” (*Colnaghi, U.S.A., Ltd. v. Jewelers Protection Servs., Ltd.*, 81 N.Y.2d 821, 823–24, [1993]). Accepting the allegations as true, marketing products as “healthy” and “protective” while utilizing ingredients that dangerously increase the risk of uterine cancer and failing to warn about the dangers of those ingredients despite alleged knowledge of those dangers is sufficient to allege gross negligence.

iv. Negligence *Per Se* (Twelfth Cause of Action)

L’Oréal USA’s motion to dismiss Plaintiff’s claims alleging negligence *per se* is denied. New York law holds defendants liable for negligence *per se* as to violations of the FDCA (see *Winans v Ornuva Foods North America Inc.*, 731 F.Supp.3d 422, 431 [EDNY 2024]).

Plaintiff's alleged violations of the FDCA based on misbranding and false or misleading labeling has long been held by the Second Circuit to give rise to a negligence *per se* claim (*see Ezagui v Dow Chemical Corp.*, 598 F2d 727, 733 [2d Cir. 1979]; *see also Sita v Danek Medical, Inc.*, 43 F.Supp.2d 245, 262 [EDNY 1999]).

v. Negligent Misrepresentation, Fraud, Fraudulent Concealment (Sixth through Eighth Causes of Action)

L'Oréal USA's motion to dismiss Plaintiff's claims alleging negligent misrepresentation, fraud, and fraudulent concealment is denied. To state a negligent misrepresentation claim, a plaintiff must allege that the defendant was "under a duty to the plaintiff to exercise reasonable care in giving the information, and plaintiff's reliance on the information must be foreseeable." (*Heard v City of New York*, 82 NY2d 66 [1993]). Accepting the allegations as true, Plaintiff adequately alleged negligent misrepresentation by stating that Defendants knew or should have known their products were unsafe yet failed to disclose the dangers to Plaintiff, who relied on Defendants' omissions when she decided to purchase their products (*see also Standish-Parkin v Lorillard Tobacco Co.*, 12 AD3d 301, 302-303 [1st Dept 2004]).

The same analysis holds true for Plaintiff's fraud and fraudulent concealment claims (*see also Rose v American Tobacco Co.*, 3 Misc.3d 1103[A] at 2 [Sup. Ct. NY Co. 2004]). Contrary to L'Oréal USA's assertion, CPLR 3016(b)'s heightened pleading standard is not meant to prevent an otherwise valid cause of action in situations where it may be "impossible to detail the circumstances constituting a fraud" (*Pludeman v Northern Leasing Systems, Inc.* 10 NY3d 486, 491 [2008] citing *Lanzi v Brooks*, 43 NY2d 778, 780 [1977]). Given Plaintiff's allegations and the procedural juncture, the Court denies L'Oréal USA's motion to dismiss Plaintiff's causes of action alleging negligent misrepresentation, fraud and fraudulent concealment.

vi. Breach of Express Warranty, Breach of Implied Warranty (Ninth and Tenth Causes of Action)

L'Oréal USA's motion to dismiss Plaintiff's claims alleging breach of express and implied warranties is denied. Pursuant to New York Uniform Commercial Code §2-313(1)(a) "any affirmation of fact or promise made by the seller to the buyer which relates to the goods and becomes part of the basis of the bargain creates an express warranty that the goods shall conform to the affirmation or promise." Likewise, §2-313(1)(b) states that "any description of the goods which is made part of the basis of the bargain creates an express warranty that the goods shall conform to the description." Here, Plaintiff alleges she relied on warranties that Defendants' products were "safe, healthy, protective, and/or natural." (NYSCEF Doc. 1 at ¶ 271). Although New York Uniform Commercial Code § 2-313(2) states a manufacturer's mere opinion or commendation of the goods does not create a warranty, as this is a pre-answer motion to dismiss further discovery is needed to ascertain whether an express warranty existed and whether Plaintiff relied on the warranty.

Moreover, there may be a breach of the implied warranty of merchantability if goods are unsafe "when used in the customary, usual and reasonably foreseeable manner" (*Denny v Ford Motor Co.*, 87 NY2d 248, 258-259 [1995]). Here, Plaintiff alleges that she developed uterine cancer from using Defendants' hair relaxer products in their usual and customary manner. These allegations are sufficient (*see generally Colarossi v C.R. Bard, Inc.*, 113 AD3d 407, 408 [1st Dept 2014]). Thus, the motion to dismiss Plaintiff's causes of action alleging a breach of express warranty and breach of implied warranty is denied.

vii. Unjust Enrichment (Thirteenth Cause of Action)

L'Oréal USA's motion to dismiss Plaintiff's claim alleging unjust enrichment is granted. As reiterated by the Court of Appeals, an unjust enrichment claim is not available if it simply

duplicates, or replaces, a conventional contract or tort claim (*Corsello v Verizon New York, Inc.*, 18 NY3d 777, 790 [2012]). Unjust enrichment is reserved for “unusual situations when, though the defendant has not breached a contract nor committed a recognized tort, circumstances create an equitable obligation running from the defendant to the plaintiff.” (*Id.*). This is not one of those cases. Nor has Plaintiff distinguished sufficiently her unjust enrichment claim from her other claims to survive dismissal. Therefore, this portion of the motion to dismiss is granted.

viii. Negligent Failure to Recall (Eleventh Cause of Action)

L’Oréal USA’s motion to dismiss Plaintiff’s claims alleging negligent failure to recall is granted. Plaintiff concedes there is no independent cause of action for “negligent failure to recall” in New York, and in any event, the failure to recall is duplicative of the numerous other negligent causes of action Plaintiff alleges – including failure to warn, ordinary negligence, gross negligence, and negligence *per se*. Therefore, this cause of action is dismissed.

ix. Punitive Damages (Fourteenth Cause of Action)

L’Oréal USA’s motion to dismiss Plaintiff’s claims alleging punitive damages is granted in part and denied in part. To the extent L’Oréal USA argues punitive damages are not an independent cause of action this is correct and the fifteenth cause of action is dismissed (*Jean v Chinitz*, 163 AD3d 497 [1st Dept 2018]). However, to the extent L’Oréal USA seeks to strike Plaintiff’s demand for punitive damages in the wherefore clauses throughout her complaint, this portion of the motion is denied. At this pre-answer stage, without the benefit of any discovery, and accepting the allegations as true, the Court finds it premature to make any ruling dismissing the claim for punitive damages (*Wholey v Amgen, Inc.*, 165 AD3d 458, 459 [1st Dept 2018]; *Sclafani v Brother Jimmy’s BBQ, Inc.*, 88 AD3d 515, 516 [1st Dept 2011]). Thus, L’Oréal USA’s motion to dismiss Plaintiff’s fifteenth cause of action which purports to assert a claim for punitive damages

is granted. However, L'Oréal USA's request that the demand for punitive damages found throughout the wherefore clauses of Plaintiff's Complaint is denied.

Accordingly, it is hereby,

ORDERED that L'Oréal USA's motion to dismiss motion to dismiss Plaintiff's Complaint is granted in part and denied in part; and it is further

ORDERED that L'Oréal USA's motion to dismiss is granted to the extent that Plaintiff's first and fourth causes of action are dismissed solely to the extent they purport to allege a claim for manufacturing defect; and it is further

ORDERED that L'Oréal USA's motion to dismiss is granted to the extent that Plaintiff's thirteenth cause of action alleging unjust enrichment and eleventh cause of action alleging negligent failure to recall are hereby dismissed; and it is further

ORDERED that L'Oréal USA's motion to dismiss is granted to the extent that Plaintiff's fourteenth cause of action alleging punitive damages is dismissed. However the motion is denied to the extent Defendant seeks dismissal of Plaintiff's demand for punitive damages in her numerous wherefore clauses; and it is further

ORDERED that the remainder of L'Oréal USA's motion to dismiss pursuant to CPLR 3211(a)(7) is denied; and it is further

ORDERED that L'Oréal USA's motion to dismiss based on federal preemption and the statute of limitations is denied, and it is further

ORDERED that within twenty days of entry, L'Oréal USA shall serve its Answer to the surviving causes of action: the first through tenth causes of action, and the twelfth cause of action; and it is further

ORDERED that within ten days of entry, counsel for Plaintiff shall serve a copy of this Decision and Order, with notice of entry, on all parties via NYSCEF.

This constitutes the Decision and Order of the Court.

9/15/2025
DATE

Mary V Rosado JSC
HON. MARY V. ROSADO, J.S.C.

CHECK ONE:	<input type="checkbox"/>	CASE DISPOSED	<input type="checkbox"/>	DENIED	<input checked="" type="checkbox"/>	NON-FINAL DISPOSITION	<input type="checkbox"/>	OTHER
APPLICATION:	<input type="checkbox"/>	GRANTED	<input type="checkbox"/>		<input checked="" type="checkbox"/>	GRANTED IN PART	<input type="checkbox"/>	
CHECK IF APPROPRIATE:	<input type="checkbox"/>	SETTLE ORDER	<input type="checkbox"/>		<input type="checkbox"/>	SUBMIT ORDER	<input type="checkbox"/>	REFERENCE
	<input type="checkbox"/>	INCLUDES TRANSFER/REASSIGN	<input type="checkbox"/>		<input type="checkbox"/>	FIDUCIARY APPOINTMENT	<input type="checkbox"/>	